Fonar (FONR) Competitors

$18.90 -0.02 (-0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$18.90 0.00 (0.00%)

As of 05:57 PM Eastern

FONR vs. KIDS, DCTH, CLPT, CV, and RXST

Should you be buying Fonar stock or one of its competitors? The main competitors of Fonar include OrthoPediatrics (KIDS), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), CapsoVision (CV), and RxSight (RXST). These companies are all part of the "medical equipment" industry.

How does Fonar compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

: OrthoPediatrics currently has a consensus price target of $24.44, suggesting a potential upside of 43.45%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, equities analysts clearly believe OrthoPediatrics is more favorable than Fonar.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.82
Fonar
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Fonar has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OrthoPediatrics $243.30M 1.80 -$39.65M -$1.68 N/A
Fonar $104.35M 1.12 $8.33M $1.13 16.73
: 69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 32.7% of OrthoPediatrics shares are held by insiders. Comparatively, 1.6% of Fonar shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: OrthoPediatrics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Fonar has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
: Fonar has a net margin of 7.13% compared to OrthoPediatrics' net margin of -16.31%. Fonar's return on equity of 4.69% beat OrthoPediatrics' return on equity.
Company Net Margins Return on Equity Return on Assets
OrthoPediatrics -16.31% -6.95% -4.86%
Fonar 7.13% 4.69% 3.48%
: In the previous week, OrthoPediatrics had 13 more articles in the media than Fonar. MarketBeat recorded 13 mentions for OrthoPediatrics and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat OrthoPediatrics' score of 0.49 indicating that Fonar is being referred to more favorably in the news media.
Company Overall Sentiment
OrthoPediatrics Neutral
Fonar Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	1.80	-$39.65M	-$1.68	N/A
Fonar	$104.35M	1.12	$8.33M	$1.13	16.73

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-6.95%	-4.86%
Fonar	7.13%	4.69%	3.48%

Company	Overall Sentiment
OrthoPediatrics	Neutral
Fonar	Very Positive

Summary

OrthoPediatrics beats Fonar on 10 of the 17 factors compared between the two stocks.

How does Fonar compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

: Delcath Systems currently has a consensus price target of $22.50, suggesting a potential upside of 95.14%. Given Delcath Systems' stronger consensus rating and higher possible upside, equities analysts clearly believe Delcath Systems is more favorable than Fonar.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Fonar
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Fonar has higher revenue and earnings than Delcath Systems. Fonar is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $85.23M 4.66 $2.70M $0.07 164.71
Fonar $104.35M 1.12 $8.33M $1.13 16.73
: 61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 1.6% of Fonar shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Fonar has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
: Fonar has a net margin of 7.13% compared to Delcath Systems' net margin of 3.17%. Fonar's return on equity of 4.69% beat Delcath Systems' return on equity.
Company Net Margins Return on Equity Return on Assets
Delcath Systems 3.17% 2.63% 2.39%
Fonar 7.13% 4.69% 3.48%
: In the previous week, Delcath Systems had 2 more articles in the media than Fonar. MarketBeat recorded 2 mentions for Delcath Systems and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat Delcath Systems' score of 0.00 indicating that Fonar is being referred to more favorably in the news media.
Company Overall Sentiment
Delcath Systems Neutral
Fonar Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.66	$2.70M	$0.07	164.71
Fonar	$104.35M	1.12	$8.33M	$1.13	16.73

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	3.17%	2.63%	2.39%
Fonar	7.13%	4.69%	3.48%

Company	Overall Sentiment
Delcath Systems	Neutral
Fonar	Very Positive

Summary

Delcath Systems and Fonar tied by winning 8 of the 16 factors compared between the two stocks.

How does Fonar compare to ClearPoint Neuro?

Fonar (NASDAQ:FONR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

: ClearPoint Neuro has a consensus price target of $14.50, indicating a potential upside of 30.63%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Fonar.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
ClearPoint Neuro
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Fonar has a net margin of 7.13% compared to ClearPoint Neuro's net margin of -69.08%. Fonar's return on equity of 4.69% beat ClearPoint Neuro's return on equity.
Company Net Margins Return on Equity Return on Assets
Fonar 7.13% 4.69% 3.48%
ClearPoint Neuro -69.08% -122.17% -40.69%
: In the previous week, ClearPoint Neuro had 1 more articles in the media than Fonar. MarketBeat recorded 1 mentions for ClearPoint Neuro and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat ClearPoint Neuro's score of 0.36 indicating that Fonar is being referred to more favorably in the media.
Company Overall Sentiment
Fonar Very Positive
ClearPoint Neuro Neutral
: 50.6% of Fonar shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 1.6% of Fonar shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Fonar has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fonar $104.35M 1.12 $8.33M $1.13 16.73
ClearPoint Neuro $36.97M 9.00 -$25.54M -$0.91 N/A
: Fonar has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Fonar	7.13%	4.69%	3.48%
ClearPoint Neuro	-69.08%	-122.17%	-40.69%

Company	Overall Sentiment
Fonar	Very Positive
ClearPoint Neuro	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.13	16.73
ClearPoint Neuro	$36.97M	9.00	-$25.54M	-$0.91	N/A

Summary

Fonar beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.

How does Fonar compare to CapsoVision?

Fonar (NASDAQ:FONR) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

: 50.6% of Fonar shares are owned by institutional investors. 1.6% of Fonar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: CapsoVision has a consensus price target of $8.50, indicating a potential upside of 20.40%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Fonar.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
CapsoVision
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
: In the previous week, CapsoVision had 2 more articles in the media than Fonar. MarketBeat recorded 2 mentions for CapsoVision and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat CapsoVision's score of 0.00 indicating that Fonar is being referred to more favorably in the media.
Company Overall Sentiment
Fonar Very Positive
CapsoVision Neutral
: Fonar has a net margin of 7.13% compared to CapsoVision's net margin of 0.00%. Fonar's return on equity of 4.69% beat CapsoVision's return on equity.
Company Net Margins Return on Equity Return on Assets
Fonar 7.13% 4.69% 3.48%
CapsoVision N/A N/A N/A
: Fonar has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fonar $104.35M 1.12 $8.33M $1.13 16.73
CapsoVision $13.55M 25.97 -$25.32M -$2.19 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Overall Sentiment
Fonar	Very Positive
CapsoVision	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Fonar	7.13%	4.69%	3.48%
CapsoVision	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.13	16.73
CapsoVision	$13.55M	25.97	-$25.32M	-$2.19	N/A

Summary

Fonar beats CapsoVision on 10 of the 16 factors compared between the two stocks.

How does Fonar compare to RxSight?

Fonar (NASDAQ:FONR) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

: 50.6% of Fonar shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.6% of Fonar shares are owned by company insiders. Comparatively, 9.6% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: RxSight has a consensus price target of $9.78, indicating a potential upside of 34.68%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Fonar.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
RxSight
3 Sell rating(s)

10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
: In the previous week, RxSight had 3 more articles in the media than Fonar. MarketBeat recorded 3 mentions for RxSight and 0 mentions for Fonar. Fonar's average media sentiment score of 1.91 beat RxSight's score of 0.00 indicating that Fonar is being referred to more favorably in the media.
Company Overall Sentiment
Fonar Very Positive
RxSight Neutral
: Fonar has a net margin of 7.13% compared to RxSight's net margin of -28.96%. Fonar's return on equity of 4.69% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
Fonar 7.13% 4.69% 3.48%
RxSight -28.96% -14.05% -12.54%
: Fonar has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
: Fonar has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fonar $104.35M 1.12 $8.33M $1.13 16.73
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Company	Overall Sentiment
Fonar	Very Positive
RxSight	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Fonar	7.13%	4.69%	3.48%
RxSight	-28.96%	-14.05%	-12.54%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.13	16.73
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A

Summary

Fonar and RxSight tied by winning 8 of the 16 factors compared between the two stocks.

Get Fonar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FONR vs. The Competition

Export

Metric	Fonar	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$116.61M	$8.14B	$6.25B	$11.87B
Dividend Yield	N/A	2.45%	2.73%	5.21%
P/E Ratio	16.73	119.73	29.04	28.47
Price / Sales	1.12	7.42	476.61	60.94
Price / Cash	9.01	17.32	27.62	36.52
Price / Book	0.73	3.52	9.67	6.67
Net Income	$8.33M	$223.69M	$3.55B	$332.53M
7 Day Performance	0.05%	0.03%	1.70%	2.01%
1 Month Performance	1.67%	10.28%	5.62%	9.20%
1 Year Performance	54.92%	0.86%	34.42%	39.59%

Fonar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FONR Fonar	2.0927 of 5 stars	$18.90 -0.1%	N/A	N/A	$116.61M	$104.35M	16.73	480	Positive News
KIDS OrthoPediatrics	3.1656 of 5 stars	$15.14 -4.3%	$24.78 +63.7%	N/A	$406.36M	$236.35M	N/A	200	Earnings Report
DCTH Delcath Systems	1.6174 of 5 stars	$10.55 -2.7%	$22.50 +113.3%	N/A	$373.49M	$85.23M	150.71	60	Upcoming Earnings
CLPT ClearPoint Neuro	1.7859 of 5 stars	$11.08 -1.2%	$14.50 +30.9%	N/A	$336.14M	$36.97M	N/A	110	Upcoming Earnings
CV CapsoVision	1.5593 of 5 stars	$6.78 +6.4%	$8.50 +25.4%	N/A	$317.47M	$13.55M	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FONR) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fonar (FONR) Competitors

FONR vs. KIDS, DCTH, CLPT, CV, and RXST

How does Fonar compare to OrthoPediatrics?

Summary

How does Fonar compare to Delcath Systems?

Summary

How does Fonar compare to ClearPoint Neuro?

Summary

How does Fonar compare to CapsoVision?

Summary

How does Fonar compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fonar (FONR) Competitors

FONR vs. KIDS, DCTH, CLPT, CV, and RXST

How does Fonar compare to OrthoPediatrics?

Summary

How does Fonar compare to Delcath Systems?

Summary

How does Fonar compare to ClearPoint Neuro?

Summary

How does Fonar compare to CapsoVision?

Summary

How does Fonar compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools